NCT04824495

Brief Summary

The aim of this study is to evaluate pro-inflammatory cytokines as well as microvesicles during the course of SARS-CoV2 infection in the context of clinical parameters.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 7, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 29, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 1, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

April 6, 2021

Status Verified

April 1, 2021

Enrollment Period

8 months

First QC Date

March 29, 2021

Last Update Submit

April 4, 2021

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

  • Cytokine level in context with clinical parameters

    2 weeks

Study Arms (1)

Patients with acute COVID-19

Diagnostic Test: Blood sample

Interventions

Blood sampleDIAGNOSTIC_TEST

Blood samples at different timepoints during SARS-CoV2 infection

Patients with acute COVID-19

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with confirmed acute SARS-CoV2 infection

You may qualify if:

  • Age \> 18 years
  • Confirmation of acute SARS-CoV2 infection
  • Ability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

RECRUITING

Related Publications (1)

  • Antoniewicz L, Melnikov G, Lyytinen G, Blomberg A, Bosson JA, Hedman L, Mobarrez F, Lundback M. Vascular Stress Markers Following Inhalation of Heated Tobacco Products: A Study on Extracellular Vesicles. Cardiovasc Toxicol. 2025 Jan;25(1):1-8. doi: 10.1007/s12012-024-09934-6. Epub 2024 Oct 29.

    PMID: 39472409DERIVED

MeSH Terms

Conditions

COVID-19

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Daniela Gompelmann

    Medical University of Vienna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniela Gompelmann

CONTACT

0043 1 40400 47730daniela.gompelmann@meduniwien.ac.at

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med.

Study Record Dates

First Submitted

March 29, 2021

First Posted

April 1, 2021

Study Start

January 7, 2021

Primary Completion

August 31, 2021

Study Completion

December 31, 2021

Last Updated

April 6, 2021

Record last verified: 2021-04

Locations

AU(1)